Efficacy of zolmitriptan nasal spray in adolescent migraine

Division of Pediatric Neurology, Children's Hospital of the King's Daughters, Eastern Virginia Medical School, Norfolk, VA 23510, USA.
PEDIATRICS (Impact Factor: 5.3). 08/2007; 120(2):390-6. DOI: 10.1542/peds.2007-0085
Source: PubMed

ABSTRACT The goal was to evaluate the efficacy and tolerability of zolmitriptan nasal spray in the treatment of adolescent migraine.
The "Double-Diamond" study used a novel, single-blind, "placebo challenge" in a multicenter, randomized, double-blind, placebo-controlled, 2-way, 2-attack, crossover design. A total of 248 US adolescent patients (12-17 years of age) with an established diagnosis of migraine, with or without aura, were enrolled. A single-blind placebo challenge was used for each migraine attack. No additional medications were taken if a headache response to the initial placebo treatment was achieved at 15 minutes; if migraine intensity remained moderate or severe, then patients treated the attack with zolmitriptan (5 mg) nasal spray or placebo according to a randomized, crossover schedule (double-blind). The primary efficacy variable was headache response at 1 hour after treatment. A comprehensive range of secondary end points included sustained headache response at 2 hours.
A total of 171 patients (mean age: 14.2 years; 57.3% female) treated > or = 1 attack with study medication (intention-to-treat population). The onset of significant pain relief was apparent 15 minutes after treatment with zolmitriptan nasal spray. At 1 hour after the dose, zolmitriptan nasal spray produced a higher headache response rate than did placebo (58.1% vs 43.3%). Zolmitriptan nasal spray was also significantly superior to placebo in improvement in pain intensity, pain-free rates, sustained resolution of headache, and resolution of associated migraine symptoms. Return to normal activities was also consistently faster with zolmitriptan nasal spray than with placebo, with less use of any escape medication. Treatment with zolmitriptan nasal spray was well tolerated.
This novel, placebo-challenge study demonstrated that zolmitriptan nasal spray was well tolerated and provided fast and significantly effective relief of migraine symptoms in the acute treatment of adolescent migraine.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Migraine headache is a common pediatric complaint among emergency department (ED) patients. There are limited trials on abortive therapies in the ED. The objective of this study was to apply a comparative effectiveness approach to investigate acute medication regimens for the prevention of ED revisits. Retrospective study using administrative data (Pediatric Health Information System) from 35 pediatric EDs (2009-2012). Children aged 7 to 18 years with a principal diagnosis of migraine headache were studied. The primary outcome was a revisit to the ED within 3 days for discharged patients. The primary analysis compared the treatment regimens and individual medications on the risk for revisit. The study identified 32 124 children with migraine; 27 317 (85%) were discharged, and 5.5% had a return ED visit within 3 days. At the index visit, the most common medications included nonopioid analgesics (66%), dopamine antagonists (50%), diphenhydramine (33%), and ondansetron (21%). Triptans and opiate medications were administered infrequently (3% each). Children receiving metoclopramide had a 31% increased odds for an ED revisit within 3 days compared with prochlorperazine. Diphenhydramine with dopamine antagonists was associated with 27% increased odds of an ED revisit compared with dopamine antagonists alone. Children receiving ondansetron had similar revisit rates to those receiving dopamine antagonists. The majority of children with migraines are successfully discharged from the ED and only 1 in 18 required a revisit within 3 days. Prochlorperazine appears to be superior to metoclopramide in preventing a revisit, and diphenhydramine use is associated with increased rates of return. Copyright © 2015 by the American Academy of Pediatrics.
    Pediatrics 01/2015; 135(2). DOI:10.1542/peds.2014-2432 · 5.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pain in children with developmental disabilities is common, but the expression of that pain is frequently ambiguous and thus clinical decision making becomes highly subjective and challenging. New assessment tools and specifi c management techniques have become available and can be used in a wide variety of clinical settings. Nevertheless, even with improved knowledge of pain, the underlying conditions, and clinical pharmacology, our ability to understand and manage pain in children with developmental disabilities remains a signifi -cant challenge. Use of a coordinated pain management approach that includes effective communication between the child, family, and allied health care professionals is essential. Key wordsAssessment–developmental disability–signifi cant neurological impairment–cerebral palsy–head injury–chronic pain–pediatric pain
    12/2007: pages 29-37;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: FDA-approved labeling contains a summary of the available and essential scientifi c information needed for the safe use of a drug for a specifi c use. With few exceptions, only a limited number of medications frequently used to treat pediatric pain or facilitate analgesia are adequately labeled for pediatric patients. Consequently, most drugs are used off-label in children. Pediatric initiatives have generated more than 300 pediatric studies resulting in new product labeling for over 120 drugs. This chapter reviews several important lessons gleaned from these studies, regulatory highlights of the drug approval process, revisions to product labeling due to the Physician Labeling Rule, and controlled substance regulations as they apply to opioids. Pediatric labeling for drugs commonly used to treat acute and chronic pain, headaches, and muscle spasm is also reviewed, highlighting the signifi cant gaps in labeling which remain, particularly for neonates and young children. Key wordsFDA–Pharmaceuticals–Physician Labeling Rule–DEA
    12/2007: pages 233-255;